Regeneron reported positive Phase 3 results for cemdisiran, a small interfering RNA therapy licensed from Alnylam, targeting generalized myasthenia gravis, a rare neuromuscular autoimmune disease. Cemdisiran monotherapy achieved significant reduction in circulating complement factor 5 and showed clinical improvements in disease activity measures compared to placebo. The company plans to file for FDA approval in early 2026. The drug’s favorable safety and efficacy profile positions it as a competitor in the evolving myasthenia gravis treatment landscape.